What is the histologic description of clear cell carcinoma (renal cell carcinoma)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Histologic Description of Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is characterized microscopically by tumor cells with clear cytoplasm due to accumulation of glycogen and lipids, arranged in nests or tubules surrounded by a rich vascular network. 1

Macroscopic Features

  • The cut surface of ccRCC tumors appears golden yellow with frequent hemorrhagic, necrotic, and cystic areas. 1

Microscopic Characteristics

Cellular Morphology

  • The hallmark "clear" appearance of the cytoplasm results from intracellular accumulation of glycogen and lipids, which are dissolved during routine histological processing, leaving empty spaces that create the characteristic clear appearance. 1

  • Tumor cells are distributed in tubular and solid areas with a very prominent capillary stroma, reflecting the highly vascularized nature of these tumors. 1

  • A variable proportion of tumor cells with granular eosinophilic cytoplasm can be observed, and in some cases, these eosinophilic cells may constitute the entire tumor mass. 1

Architectural Patterns

  • Cells are arranged in nests or tubules surrounded by an extensive network of thin-walled blood vessels. 1

  • The multilocular cystic variant, composed entirely of numerous cysts lined by clear cells, represents a low-aggressivity variant of ccRCC. 1

Nuclear Grading

  • The Fuhrman grading system is the most widely used, defining four nuclear grades (1-4) based on increasing nuclear size, irregularity, and nucleolar prominence, with demonstrated prognostic value. 1

Molecular and Genetic Features

  • ccRCC is associated with VHL gene mutations and chromosomal abnormalities at 3p25-26 in 34-56% of sporadic cases. 1

  • VHL inactivation leads to constitutive activation of hypoxia-inducible factors (HIFs), resulting in a pseudo-hypoxic phenotype that drives the metabolic reprogramming characteristic of these tumors. 2, 3

Important Diagnostic Considerations

  • Clear cells are not unique to ccRCC and can be observed in papillary RCC, chromophobe RCC, and MiT family translocation RCC, requiring careful evaluation of cytological features, growth pattern, immunophenotype, and genetic alterations for proper diagnosis. 1

  • Eosinophilic areas within ccRCC are associated with higher grade and more aggressive tumors, displaying higher proliferative drive, lower differentiation, and exclusive TP53 mutations. 2

  • Sarcomatoid differentiation can occur in any RCC type and is no longer considered a separate entity but rather represents tumor progression, with enrichment in TP53 and CDKN2A mutations. 1

Epidemiology

  • ccRCC represents 70-85% of all sporadic RCC cases in adults, making it the most frequent subtype. 1, 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Renal Cell Carcinoma Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Renal Cell Carcinoma Characteristics and Classification

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the further management for a patient with a 3.6x3.9x3.8 cm renal mass, clear cell histology, post radical nephrectomy (complete removal of the kidney)?
What are the most concerning ultrasound features and treatment options for Renal Cell Carcinoma (RCC)?
For solitary metastases of renal cell carcinoma (RCC), should a biopsy be performed first or should the metastasis be removed?
What is the approach to evaluate a patient with Renal Cell Carcinoma (RCC) in terms of history taking, blood investigations, and imaging studies?
What are the management strategies for Renal Cell Carcinoma (RCC), including diagnosis, treatment, and follow-up?
What are the considerations for using semaglutide (glucagon-like peptide-1 receptor agonist) in a patient with type 2 diabetes and a history of cardiovascular disease who has or is at risk for diabetic retinopathy?
Can I give metformin (biguanide) 1000 mg plus dapagliflozin (SGLT2 inhibitor) 10 mg plus gliclazide (sulfonylurea) 60 mg to a patient with impaired renal function and poorly controlled diabetes?
What is the recommended treatment for a patient with otitis externa?
What is thalamic pain syndrome and how is it treated in patients with a history of stroke or traumatic brain injury?
What are the alternative treatments for a patient with Pneumocystis pneumonia (PCP) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX)?
What is the recommended post-operative rehabilitation protocol for a patient with a clavicle fracture treated with plate fixation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.